THE CHOICE OF THE ANTIHYPERTENSIVE DRUG IN SPECIAL CONDITIONS: EVIDENCE-BASED DATA IN CO-MORBID CARDIOVASCULAR DISEASES
https://doi.org/10.18705/1607-419X-2014-20-3-147-151
Abstract
The articles reviews the main approaches to the choice of the antihypertensive drug in cardiovascular comorbidities based on the data from the worldwide guidelines by the Joint National Committee of the USA, European Society of Cardiology / European Society of Hypertension, American Society of Hypertension /International Society of Hypertension.
About the Authors
I. S. Korostovtseva
Almazov Medical Research Centre, St Petersburg
Russian Federation
Corresponding author: Almazov Medical Research Centre, 2 Akkuratovа st., St Petersburg, Russia, 197341. Phone: +7 (812) 702–68–10. E-mail: korostovtseva@almazovcentre.ru (Lyudmila S. Korostovtseva, MD, PhD, a Researcher at the Sleep Medicine Laboratory of the Hypertension Research Department at the Almazov Medical Research Centre).
Russian Federation
Corresponding author: Almazov Medical Research Centre, 2 Akkuratovа st., St Petersburg, Russia, 197341. Phone: +7 (812) 702–68–10. E-mail: korostovtseva@almazovcentre.ru (Lyudmila S. Korostovtseva, MD, PhD, a Researcher at the Sleep Medicine Laboratory of the Hypertension Research Department at the Almazov Medical Research Centre).
N. E. Zvartau
Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
A. O. Konradi
Almazov Medical Research Centre, St Petersburg
Russian Federation
Russian Federation
References
1. James P.A., Oparil S., Carter B.L. et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) // J. Am. Med. Assoc. — 2014. Vol. 311, № 5. — Р. 507–520. doi:10.1001/jama.2013.284427
2. Weber M.A., Schiffrin E.L., White W.B. et al. Clinical practice guidelines for the management of hypertension in the ommunity a statement by the American society of hypertension
3. and the International society of hypertension // J. Hypertens. — 2014. — Vol. 32, № 1. — Р. 3–15.
4. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2013. — Vol. 31, № 7. — Р. 281–357. doi: 10.1097/01.hjh.0000431740.32696.cc.
5. Баранова Е.И. Лечение артериальной гипертензии в особых группах пациентов (рекомендации по лечению артериальной гипертензии 2013 года Европейского общества по артериальной гипертензии и Европейского общества кардиологов) // Артериальная гипертензия. — 2014. — Т. 20, № 1. — С. 38–44. / Baranova E.I. Treatment strategies of arterial hypertension in special conditions (2013 European Society of Hypertension and European Society of Cardiology guidelines for the management of arterial hypertension) // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2014. — Vol. 20, № 1. — P. 38–44 [Russian].
6. Котовская Ю.В., Кравцова О.А., Павлова Е.А. Новое в терапевтических стратегиях // Артериальная гипертензия. — 2014. — Т. 20, № 1. — С. 27–33. / Kotovskaya Y.V., Kravtsova O.V., Pavlova E.A. Novel therapeutic strategies // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2014. — Vol. 20, № 1. — P. 27–33 [Russian].
7. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies // Hypertension. — 2009. —Vol. 54, № 5. — P. 1084–1091.
8. Okin P.M., Devereux R.B., Jern S. et al. Regression of electrocardiographic left ventricular hypertrophy by losartan vs. atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study // Circulation. — 2003. — Vol. 108, № 6. — P. 684–690.
9. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // Br. Med. J. — 2009. — Vol. 338. — P. b1665.
10. Borghi C., Bacchelli S., Degli Esposti D., Bignamini A., Magnani B., Ambrosioni E. Effects of the administration of an angiotensin converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long term evaluation // Am. J. Hypertens. — 1999. — Vol. 12. — P. 665–672.
11. Gustafsson F., Kober L., Torp-Pedersen C. et al. Long-term prognosis after acute myocardial infarction in patients with a his-tory of arterial hypertension // Eur. Heart J. — 1998. — Vol. 19, № 4. — P. 588–594.
12. Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.
13. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — P. 1225–1237.
14. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively- designed overviews of randomised trials // Lancet. — 2003. — Vol. 362, № 9246. — P. 1527–1535.
15. Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.
16. Raphael C.E., Whinnett Z.I., Davies J.E. et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure // Heart. — 2009. — Vol. 95, № 1. — P. 56–62.
17. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial ibrillation and subsequent stroke compared with atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. — 2005. — Vol. 45, № 5. — P. 712–719.
18. Vermes E., Tardif J.C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial ibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials // Circulation. — 2003. — Vol. 107, № 23. — P. 2926–2931.
19. Schmieder R.E., Kjeldsen S.E., Julius S., McInnes G.T., Zanchetti A., Hua T.A. Reduced incidence of new-onset atrial i-brillation with angiotensin II receptor blockade: the VALUE trial // J. Hypertens. — 2008. — Vol. 26, № 3. — P. 403–411.
20. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. — 2001. — Vol. 345, № 23. — P. 1667–1675.
21. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial ibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program // Am. Heart J. — 2006. — Vol. 152, № 1. — P. 86–92.
22. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial ibrillation: an update of the 2010 ESC Guidelines for the management of atrial ibrillation // Eur. Heart J. — 2012. — Vol. 33, № 21. — P. 2719–3274.
23. Vahanian A., Alieri O., Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart J. — 2012. — Vol. 33. — P. 2451–2496.
24. ACC/ESC Expert consensus document American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines // Eur. Heart J. — 2003. — Vol. 24, № 21. — P. 1965–1991.
25. Guidelines on management (diagnosis and treatment) of syncope — update 2004. The Task force on syncope, European Society of Cardiology // Europace. — 2004. — Vol. 6, № 6. — Р. 467–537.
26. Wong A.K., Lord S.R., Sturnieks D.L., Delbaere K., Trollor J.N., Close J.C. Angiotensin system-blocking medications are associated with fewer falls over 12 months in community dwellingolder people // J. Am. Geriatr. Soc. — 2013. — Vol. 61, № 5. — Р. 776–781.
27. Shibao C., Lipsitz L.A., Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension // J. Clin. Hypertens. (Greenwich). — 2013. — Vol. 15, № 3. — Р. 147–153.
Review
For citations:
Korostovtseva I.S., Zvartau N.E., Konradi A.O. THE CHOICE OF THE ANTIHYPERTENSIVE DRUG IN SPECIAL CONDITIONS: EVIDENCE-BASED DATA IN CO-MORBID CARDIOVASCULAR DISEASES. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(3):147-151. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-3-147-151
Views:
934
Email this article 